Topadur Pharma AG’s Post

🤝 #Productive #partnerships between #biotech and #CDMOs are key to the #success of joint #drug projects, whether in #development or commercial #manufacturing. 👉 At this year's #BioIntegrates2024, a panel discussion will explore facets of this fundamental topic. Neil Jones, Chief Commercial Officer at CDMO Aenova, gives 3 #tips for productive partnerships today. Listen in!

Thrilled to have Mamas L. attending #BIOEurope in Sweden, Stockholm, where leaders in biopharma are diving into the critical challenges and fast-evolving dynamics of the industry. From R&D to market access and launch excellence, this congress is packed with data-driven insights, impactful case studies, and forward-thinking discussions that span the entire biopharma value chain. #biopharma #marketaccess #launchexcellence #newinsights

Due to record demand, we are now sold out of in-person passes to attend Bio€quity Europe in San Sebastián. You may still attend this VIP event via a Digital Pass, which allows you to: ➤ Schedule virtual partnering meetings with Bio€quity delegates May 21-22 ➤ Watch all session recordings for 30 days after the event. ➤ Receive the exclusive conference report from Insights Partner McKinsey & Company plus the Bio€quity “Scene Setter” report from BioCentury Inc. Register for a digital pass: https://loom.ly/HNklMqQ If you wish to attend #BioEquityEurope in-person, please join the Wait List: https://loom.ly/mo-dKj0 Those on the Wait List who have registered for a Digital Pass will receive priority review. Please ensure you have an in-person ticket before you book travel. #biotech #biopharma #venturecapital #drugdevelopment #businessdevelopment #pharma #investor #investors #lifesciences #VCs

📆 There’s just 4 days left to apply to present you company at BIO-Europe this November, 4–6, in Stockholm. 🇸🇪 🚀 Check out the benefits of presenting: • INCREASED VISIBILITY. Raise your company's profile and generate interest among top-tiers investors, biopharma execs and potential partners attending BIO-Europe. • PRE-RECORD YOUR PITCH. All BIO-Europe presenters will have the opportunity to pre-record their pitch to be watched on demand for all registered attendees up to 3 weeks before the event. • MORE MEETINGS. Your presentation in partneringONE® will include a link for attendees to schedule one-to-one meetings with your company. Statistics from previous events show that presenting companies receive up to 20% more meeting requests. Apply to present before September 12th >> http://spr.ly/6042YqnyG #BIOEurope #EBDGroup #Present #Innovation #Stockholm #Sweden

Excited for the Pharma CI Conference in Newark! I’ll be representing SI Insights at this year’s Pharma CI conference and am looking forward to connecting with fellow professionals. Here’s what you can expect from us: 🌍 Comprehensive Coverage of the Indian, African, and Southeast Asian pharma markets for your consulting and competitive intelligence (CI) needs. 🌎 Expertise in US and EU pharma markets for tailored CI projects. Whether you're looking for insights, collaboration, or new opportunities, I’d love to meet and discuss how SI Insights can support your pharma CI and consulting goals. Let’s connect! 👋 #PharmaCI #PharmaConsulting #CompetitiveIntelligence #SIInsights #PharmaMarkets #IndiaPharma #AfricanPharma #SoutheastAsiaPharma #USPharma #EUPharma #PharmaExpertise

Heading to #bio2024 next week in San Diego, feel free to reach out and hopefully we can connect at the conference at some point. If nothing else, stop by AsymBio & Clin-nov Medical's reception for some #networking at Biotechnology Innovation Organization's conference. Details are listed below. #biotech #pharma #biotechnology #pharmaceuticals #pharmaceutical #lifescience #lifescience #drugdevelopment #drugdiscovery #drugmanufacturing #clinicaltrials #cdmo #cro

This week, the Lyfegen team will be attending two major events across different continents! From October 9th to 11th, we’ll be at the EPP - Pricing Platform Platform Life Sciences Pricing Forum 2024 in Berlin, the premier event for Pricing, Market Access, and Reimbursement leaders. Our CXO & Founder, Nico Julian Mros, will host the session: “𝗪𝗵𝘆 𝗦𝗮𝘆𝗶𝗻𝗴 ‘𝗜𝘁’𝘀 𝗧𝗼𝗼 𝗗𝗶𝗳𝗳𝗶𝗰𝘂𝗹𝘁’ 𝗡𝗼 𝗟𝗼𝗻𝗴𝗲𝗿 𝗪𝗼𝗿𝗸𝘀 𝗶𝗻 𝗩𝗮𝗹𝘂𝗲-𝗕𝗮𝘀𝗲𝗱 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗻𝗴.” At the same time, on October 10th, we’ll be in St. John’s, NL, for the NLHS Innovation Summit, where Ina Hasani, MSc, MBA our Director, Sales & Business Development, will lead the session: “𝗙𝗮𝘀𝘁-𝘁𝗿𝗮𝗰𝗸𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗕𝗲𝘁𝘁𝗲𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗢𝘂𝘁𝗰𝗼𝗺𝗲𝘀.” We’re excited to showcase how Lyfegen is driving growth and sustainability for manufacturers worldwide. Book a demo with us before the events here: https://lnkd.in/dn6Nh7sh. Don’t miss your chance to connect with us in Berlin or St. John’s and discover how we can support your pricing and market access needs. Simon Farrow #LifeSciences #PricingForum #MarketAccess #Pharmaceuticals #MedTech #Biotech #HealthcareInnovation #ReimbursementStrategies #PricingStrategies #SustainabilityInHealthcare #BerlinEvents #Lyfegen #EPPForum #StJohnsEvents

Let's take a coffee break together amidst the conference busyness and discuss how we can support your program's development and regulatory pathway! PM us! #regulatoryaffairs #FDA #biotech #pharmaceutical #productdevelopment #startup #lifesciences #clinical #clinicaldevelopment #preclinical #medicalwriting #CMC #eCTD #EMA #TGA #BioEurope #Bio #conference

🌟 𝐇𝐮𝐠𝐞 𝐭𝐡𝐚𝐧𝐤𝐬 𝐭𝐨 𝐨𝐮𝐫 𝐟𝐚𝐧𝐭𝐚𝐬𝐭𝐢𝐜 𝐩𝐚𝐧𝐞𝐥𝐢𝐬𝐭𝐬 𝐟𝐨𝐫 𝐬𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐜𝐫𝐮𝐜𝐢𝐚𝐥 𝐫𝐨𝐥𝐞 𝐨𝐟 𝐂𝐌𝐂 𝐢𝐧 𝐭𝐡𝐞 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐫𝐨𝐚𝐝𝐦𝐚𝐩! 🌟 Their insights made it clear that CMC decisions can significantly impact asset valuation and out-licensing potential. A standout moment? 🚨 Corinne Venot’s eye-opening statistic: 𝐨𝐯𝐞𝐫 𝟓𝟎% 𝐨𝐟 𝐝𝐮𝐞 𝐝𝐢𝐥𝐢𝐠𝐞𝐧𝐜𝐞𝐬 𝐟𝐚𝐢𝐥, 𝐨𝐫 𝐚𝐬𝐬𝐞𝐭𝐬 𝐚𝐫𝐞 𝐝𝐞𝐯𝐚𝐥𝐮𝐞𝐝, 𝐝𝐮𝐞 𝐭𝐨 𝐂𝐌𝐂 𝐢𝐬𝐬𝐮𝐞𝐬 in her Pharma licensing experience. And Johannes Roebers shared a compelling case about a topical product that reached Phase III, only to fail because formulation and delivery systems were overlooked early on—an end to what could’ve been a great biotech story. 💡 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 𝐟𝐨𝐫 𝐁𝐢𝐨𝐭𝐞𝐜𝐡𝐬: 1.𝗜𝗻𝘃𝗲𝘀𝘁 𝗶𝗻 𝗖𝗠𝗖! Biotechs often underestimate CMC strategy and execution budgets. 2. 𝗗𝗲𝘀𝗶𝗴𝗻 𝘁𝗵𝗲 𝗖𝗠𝗖 𝗿𝗼𝗮𝗱𝗺𝗮𝗽 𝗲𝗮𝗿𝗹𝘆 to ensure your tox material matches the future GMP process/platform/CDMO. 3. 𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗲 𝗘𝘅𝗽𝗲𝗿𝘁𝘀 with deep experience in the field to avoid later pitfalls, in both Drug Substance and Formulation/Drug Product aspects. 4. 𝗨𝘀𝗲 𝗣𝗿𝗼𝘃𝗲𝗻 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺𝘀/𝗖𝗗𝗠𝗢𝘀. Stick to innovating the asset/not the process—ensure future CMC transferability to a commercial Pharma/CDMO site. 5. 𝗧𝗵𝗶𝗻𝗸 𝗕𝗲𝘆𝗼𝗻𝗱 𝗣𝗵𝗮𝘀𝗲 𝗜! Plan for scalability, transferability, and early de-risking of commercial COGS with market access in mind. Our discussion highlighted that 𝗖𝗠𝗖 𝗰𝗮𝗻 𝗲𝗶𝘁𝗵𝗲𝗿 𝗼𝗽𝗲𝗻 𝗱𝗼𝗼𝗿𝘀 𝗳𝗼𝗿 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗼𝗿 𝗰𝗿𝗲𝗮𝘁𝗲 𝗿𝗼𝗮𝗱𝗯𝗹𝗼𝗰𝗸𝘀 at the out-licensing stage. And while CMC might be seen as a “boring topic” by investors (thanks Matthieu Coutet for the candid statement!), it’s under more scrutiny than ever. 🚀  𝗠𝗲𝘀𝘀𝗮𝗴𝗲 𝘁𝗼 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵𝘀: 𝗺𝗮𝗸𝗲 𝗖𝗠𝗖 𝗮 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝘆—𝘁𝗵𝗶𝘀 𝗲𝗮𝗿𝗹𝘆 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝘄𝗶𝗹𝗹 𝘀𝗲𝘁 𝘆𝗼𝘂 𝘂𝗽 𝗳𝗼𝗿 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝘀𝘂𝗰𝗰𝗲𝘀𝘀! #BioEurope #ProductDevelopment #CMC #AssetValuation #BioPharma #ProductLifeGroup #Sofinnova #Beigene # AGCBiologics #NioSync

If you are attending Biotechnology Innovation Organization's #BIO2024 next month, let me know and we can arrange some to chat. Also, AsymBio and Clin-nov Medical will be hosting a reception as well. Details are attached. #biotech #pharma #lifesciences #drugdevelopment #drugdiscovery #drugmanufacturing #biotechnology #pharmaceuticals